Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.
BACKGROUND This study evaluated the real-world efficacy, safety, and prognostic factors associated with progression-free survival (PFS) in patients with HR-positive/HER2-negative metastatic breast cancer treated with ribociclib. RESEARCH DESIGN AND METHODS This retrospective single-center study included 110 patients...